nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—type 2 diabetes mellitus—obesity	0.588	1	CtDrD
Gliclazide—ALB—obesity	0.095	1	CbGaD
Gliclazide—CYP2C9—Phentermine—obesity	0.0291	0.269	CbGbCtD
Gliclazide—CYP2C9—Bupropion—obesity	0.0247	0.229	CbGbCtD
Gliclazide—CYP2C19—Cimetidine—obesity	0.0218	0.202	CbGbCtD
Gliclazide—CYP2C9—Cimetidine—obesity	0.0182	0.168	CbGbCtD
Gliclazide—CYP2C19—Topiramate—obesity	0.0143	0.132	CbGbCtD
Gliclazide—VEGFA—islet of Langerhans—obesity	0.00134	0.0926	CbGeAlD
Gliclazide—VEGFA—adrenal cortex—obesity	0.00106	0.0734	CbGeAlD
Gliclazide—ALB—gall bladder—obesity	0.000962	0.0666	CbGeAlD
Gliclazide—KCNJ11—islet of Langerhans—obesity	0.000956	0.0662	CbGeAlD
Gliclazide—ABCC8—islet of Langerhans—obesity	0.00088	0.061	CbGeAlD
Gliclazide—VEGFA—pituitary gland—obesity	0.000856	0.0593	CbGeAlD
Gliclazide—VEGFA—adipose tissue—obesity	0.000852	0.059	CbGeAlD
Gliclazide—VEGFA—adrenal gland—obesity	0.000764	0.053	CbGeAlD
Gliclazide—Glyburide—CPT1A—obesity	0.000696	0.604	CrCbGaD
Gliclazide—KCNJ11—cardiovascular system—obesity	0.000691	0.0479	CbGeAlD
Gliclazide—ABCC8—cardiovascular system—obesity	0.000637	0.0441	CbGeAlD
Gliclazide—VEGFA—liver—obesity	0.000598	0.0414	CbGeAlD
Gliclazide—ABCC8—pituitary gland—obesity	0.000564	0.0391	CbGeAlD
Gliclazide—KCNJ11—adrenal gland—obesity	0.000547	0.0379	CbGeAlD
Gliclazide—ABCC8—adrenal gland—obesity	0.000504	0.0349	CbGeAlD
Gliclazide—KCNJ11—endocrine gland—obesity	0.000474	0.0329	CbGeAlD
Gliclazide—ABCC8—endocrine gland—obesity	0.000437	0.0303	CbGeAlD
Gliclazide—Glipizide—PPARG—obesity	0.000386	0.335	CrCbGaD
Gliclazide—ALB—adrenal gland—obesity	0.000361	0.025	CbGeAlD
Gliclazide—CYP2C19—digestive system—obesity	0.000305	0.0211	CbGeAlD
Gliclazide—CYP2C9—cardiovascular system—obesity	0.000285	0.0197	CbGeAlD
Gliclazide—ALB—liver—obesity	0.000282	0.0195	CbGeAlD
Gliclazide—CYP2C19—endocrine gland—obesity	0.000252	0.0174	CbGeAlD
Gliclazide—CYP2C9—digestive system—obesity	0.000236	0.0164	CbGeAlD
Gliclazide—CYP2C19—liver—obesity	0.000227	0.0157	CbGeAlD
Gliclazide—CYP2C9—endocrine gland—obesity	0.000195	0.0135	CbGeAlD
Gliclazide—CYP2C9—liver—obesity	0.000176	0.0122	CbGeAlD
Gliclazide—Nausea—Diethylpropion—obesity	9.28e-05	0.000768	CcSEcCtD
Gliclazide—Erythema multiforme—Bupropion—obesity	9.21e-05	0.000763	CcSEcCtD
Gliclazide—Hypoglycaemia—Topiramate—obesity	9.19e-05	0.000762	CcSEcCtD
Gliclazide—Angioedema—Orlistat—obesity	9.18e-05	0.000761	CcSEcCtD
Gliclazide—Tremor—Sibutramine—obesity	9.11e-05	0.000755	CcSEcCtD
Gliclazide—Eye disorder—Bupropion—obesity	9.1e-05	0.000754	CcSEcCtD
Gliclazide—Tinnitus—Bupropion—obesity	9.08e-05	0.000752	CcSEcCtD
Gliclazide—Malaise—Orlistat—obesity	9.06e-05	0.000751	CcSEcCtD
Gliclazide—Flushing—Bupropion—obesity	9.04e-05	0.000749	CcSEcCtD
Gliclazide—Ill-defined disorder—Sibutramine—obesity	9.03e-05	0.000748	CcSEcCtD
Gliclazide—Hyponatraemia—Topiramate—obesity	9.01e-05	0.000746	CcSEcCtD
Gliclazide—Anaemia—Sibutramine—obesity	8.99e-05	0.000745	CcSEcCtD
Gliclazide—Diplopia—Topiramate—obesity	8.97e-05	0.000743	CcSEcCtD
Gliclazide—Pain in extremity—Topiramate—obesity	8.97e-05	0.000743	CcSEcCtD
Gliclazide—Osteoarthritis—Topiramate—obesity	8.97e-05	0.000743	CcSEcCtD
Gliclazide—Agitation—Sibutramine—obesity	8.94e-05	0.000741	CcSEcCtD
Gliclazide—Angioedema—Sibutramine—obesity	8.89e-05	0.000736	CcSEcCtD
Gliclazide—Palpitations—Orlistat—obesity	8.88e-05	0.000736	CcSEcCtD
Gliclazide—Nausea—Cimetidine—obesity	8.83e-05	0.000731	CcSEcCtD
Gliclazide—Malaise—Sibutramine—obesity	8.77e-05	0.000727	CcSEcCtD
Gliclazide—Cough—Orlistat—obesity	8.77e-05	0.000727	CcSEcCtD
Gliclazide—Chills—Bupropion—obesity	8.74e-05	0.000724	CcSEcCtD
Gliclazide—Convulsion—Orlistat—obesity	8.71e-05	0.000721	CcSEcCtD
Gliclazide—Leukopenia—Sibutramine—obesity	8.71e-05	0.000721	CcSEcCtD
Gliclazide—Arrhythmia—Bupropion—obesity	8.7e-05	0.000721	CcSEcCtD
Gliclazide—Palpitations—Sibutramine—obesity	8.6e-05	0.000712	CcSEcCtD
Gliclazide—Chest pain—Orlistat—obesity	8.56e-05	0.000709	CcSEcCtD
Gliclazide—Myalgia—Orlistat—obesity	8.56e-05	0.000709	CcSEcCtD
Gliclazide—Loss of consciousness—Sibutramine—obesity	8.55e-05	0.000708	CcSEcCtD
Gliclazide—Mental disorder—Bupropion—obesity	8.53e-05	0.000707	CcSEcCtD
Gliclazide—Anxiety—Orlistat—obesity	8.53e-05	0.000706	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Orlistat—obesity	8.5e-05	0.000704	CcSEcCtD
Gliclazide—Cough—Sibutramine—obesity	8.49e-05	0.000703	CcSEcCtD
Gliclazide—Malnutrition—Bupropion—obesity	8.48e-05	0.000703	CcSEcCtD
Gliclazide—Discomfort—Orlistat—obesity	8.45e-05	0.0007	CcSEcCtD
Gliclazide—Convulsion—Sibutramine—obesity	8.43e-05	0.000698	CcSEcCtD
Gliclazide—Hypertension—Sibutramine—obesity	8.4e-05	0.000696	CcSEcCtD
Gliclazide—Dry mouth—Orlistat—obesity	8.37e-05	0.000693	CcSEcCtD
Gliclazide—Flatulence—Bupropion—obesity	8.36e-05	0.000692	CcSEcCtD
Gliclazide—Tension—Bupropion—obesity	8.32e-05	0.000689	CcSEcCtD
Gliclazide—Chest pain—Sibutramine—obesity	8.28e-05	0.000686	CcSEcCtD
Gliclazide—Arthralgia—Sibutramine—obesity	8.28e-05	0.000686	CcSEcCtD
Gliclazide—Myalgia—Sibutramine—obesity	8.28e-05	0.000686	CcSEcCtD
Gliclazide—Anxiety—Sibutramine—obesity	8.25e-05	0.000684	CcSEcCtD
Gliclazide—Nervousness—Bupropion—obesity	8.24e-05	0.000682	CcSEcCtD
Gliclazide—Back pain—Bupropion—obesity	8.2e-05	0.00068	CcSEcCtD
Gliclazide—Discomfort—Sibutramine—obesity	8.18e-05	0.000678	CcSEcCtD
Gliclazide—Infection—Orlistat—obesity	8.15e-05	0.000675	CcSEcCtD
Gliclazide—Dry mouth—Sibutramine—obesity	8.1e-05	0.000671	CcSEcCtD
Gliclazide—Toxic epidermal necrolysis—Topiramate—obesity	8.08e-05	0.000669	CcSEcCtD
Gliclazide—Nervous system disorder—Orlistat—obesity	8.04e-05	0.000666	CcSEcCtD
Gliclazide—Confusional state—Sibutramine—obesity	8.01e-05	0.000663	CcSEcCtD
Gliclazide—Skin disorder—Orlistat—obesity	7.97e-05	0.00066	CcSEcCtD
Gliclazide—Tremor—Bupropion—obesity	7.95e-05	0.000658	CcSEcCtD
Gliclazide—Gastritis—Topiramate—obesity	7.94e-05	0.000658	CcSEcCtD
Gliclazide—Hyperhidrosis—Orlistat—obesity	7.93e-05	0.000657	CcSEcCtD
Gliclazide—Infection—Sibutramine—obesity	7.89e-05	0.000653	CcSEcCtD
Gliclazide—Ill-defined disorder—Bupropion—obesity	7.87e-05	0.000652	CcSEcCtD
Gliclazide—Anaemia—Bupropion—obesity	7.84e-05	0.000649	CcSEcCtD
Gliclazide—Abdominal distension—Topiramate—obesity	7.81e-05	0.000647	CcSEcCtD
Gliclazide—Agitation—Bupropion—obesity	7.79e-05	0.000646	CcSEcCtD
Gliclazide—Thrombocytopenia—Sibutramine—obesity	7.77e-05	0.000644	CcSEcCtD
Gliclazide—Asthma—Topiramate—obesity	7.75e-05	0.000642	CcSEcCtD
Gliclazide—Angioedema—Bupropion—obesity	7.75e-05	0.000642	CcSEcCtD
Gliclazide—Tachycardia—Sibutramine—obesity	7.75e-05	0.000642	CcSEcCtD
Gliclazide—Skin disorder—Sibutramine—obesity	7.71e-05	0.000639	CcSEcCtD
Gliclazide—Hyperhidrosis—Sibutramine—obesity	7.67e-05	0.000636	CcSEcCtD
Gliclazide—Malaise—Bupropion—obesity	7.65e-05	0.000634	CcSEcCtD
Gliclazide—Leukopenia—Bupropion—obesity	7.59e-05	0.000629	CcSEcCtD
Gliclazide—Angina pectoris—Topiramate—obesity	7.55e-05	0.000626	CcSEcCtD
Gliclazide—Palpitations—Bupropion—obesity	7.49e-05	0.000621	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Orlistat—obesity	7.47e-05	0.000619	CcSEcCtD
Gliclazide—Bronchitis—Topiramate—obesity	7.46e-05	0.000618	CcSEcCtD
Gliclazide—Loss of consciousness—Bupropion—obesity	7.45e-05	0.000618	CcSEcCtD
Gliclazide—Abdominal discomfort—Topiramate—obesity	7.43e-05	0.000616	CcSEcCtD
Gliclazide—Insomnia—Orlistat—obesity	7.42e-05	0.000615	CcSEcCtD
Gliclazide—Hypotension—Sibutramine—obesity	7.42e-05	0.000615	CcSEcCtD
Gliclazide—Cough—Bupropion—obesity	7.4e-05	0.000613	CcSEcCtD
Gliclazide—Paraesthesia—Orlistat—obesity	7.37e-05	0.00061	CcSEcCtD
Gliclazide—Pancytopenia—Topiramate—obesity	7.36e-05	0.00061	CcSEcCtD
Gliclazide—Convulsion—Bupropion—obesity	7.35e-05	0.000609	CcSEcCtD
Gliclazide—Hypertension—Bupropion—obesity	7.32e-05	0.000607	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Sibutramine—obesity	7.23e-05	0.000599	CcSEcCtD
Gliclazide—Dyspepsia—Orlistat—obesity	7.22e-05	0.000598	CcSEcCtD
Gliclazide—Arthralgia—Bupropion—obesity	7.22e-05	0.000598	CcSEcCtD
Gliclazide—Myalgia—Bupropion—obesity	7.22e-05	0.000598	CcSEcCtD
Gliclazide—Chest pain—Bupropion—obesity	7.22e-05	0.000598	CcSEcCtD
Gliclazide—Upper respiratory tract infection—Topiramate—obesity	7.21e-05	0.000597	CcSEcCtD
Gliclazide—Anxiety—Bupropion—obesity	7.19e-05	0.000596	CcSEcCtD
Gliclazide—Insomnia—Sibutramine—obesity	7.18e-05	0.000595	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Bupropion—obesity	7.17e-05	0.000594	CcSEcCtD
Gliclazide—Erectile dysfunction—Topiramate—obesity	7.14e-05	0.000592	CcSEcCtD
Gliclazide—Discomfort—Bupropion—obesity	7.13e-05	0.000591	CcSEcCtD
Gliclazide—Paraesthesia—Sibutramine—obesity	7.13e-05	0.000591	CcSEcCtD
Gliclazide—Glyburide—ALB—obesity	7.09e-05	0.0615	CrCbGaD
Gliclazide—Gastrointestinal disorder—Orlistat—obesity	7.08e-05	0.000587	CcSEcCtD
Gliclazide—Dyspnoea—Sibutramine—obesity	7.08e-05	0.000586	CcSEcCtD
Gliclazide—Photosensitivity reaction—Topiramate—obesity	7.08e-05	0.000586	CcSEcCtD
Gliclazide—Fatigue—Orlistat—obesity	7.07e-05	0.000586	CcSEcCtD
Gliclazide—Dry mouth—Bupropion—obesity	7.06e-05	0.000585	CcSEcCtD
Gliclazide—Somnolence—Sibutramine—obesity	7.06e-05	0.000585	CcSEcCtD
Gliclazide—Weight increased—Topiramate—obesity	7.06e-05	0.000585	CcSEcCtD
Gliclazide—Pain—Orlistat—obesity	7.02e-05	0.000581	CcSEcCtD
Gliclazide—Hyperglycaemia—Topiramate—obesity	6.99e-05	0.000579	CcSEcCtD
Gliclazide—Dyspepsia—Sibutramine—obesity	6.99e-05	0.000579	CcSEcCtD
Gliclazide—Confusional state—Bupropion—obesity	6.98e-05	0.000578	CcSEcCtD
Gliclazide—Pneumonia—Topiramate—obesity	6.95e-05	0.000576	CcSEcCtD
Gliclazide—Depression—Topiramate—obesity	6.89e-05	0.000571	CcSEcCtD
Gliclazide—Infection—Bupropion—obesity	6.88e-05	0.00057	CcSEcCtD
Gliclazide—Stevens-Johnson syndrome—Topiramate—obesity	6.85e-05	0.000568	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Sibutramine—obesity	6.85e-05	0.000568	CcSEcCtD
Gliclazide—Renal failure—Topiramate—obesity	6.8e-05	0.000563	CcSEcCtD
Gliclazide—Constipation—Sibutramine—obesity	6.79e-05	0.000562	CcSEcCtD
Gliclazide—Pain—Sibutramine—obesity	6.79e-05	0.000562	CcSEcCtD
Gliclazide—Nervous system disorder—Bupropion—obesity	6.79e-05	0.000562	CcSEcCtD
Gliclazide—Neuropathy peripheral—Topiramate—obesity	6.78e-05	0.000561	CcSEcCtD
Gliclazide—Thrombocytopenia—Bupropion—obesity	6.78e-05	0.000561	CcSEcCtD
Gliclazide—Feeling abnormal—Orlistat—obesity	6.76e-05	0.00056	CcSEcCtD
Gliclazide—Tachycardia—Bupropion—obesity	6.75e-05	0.00056	CcSEcCtD
Gliclazide—Skin disorder—Bupropion—obesity	6.72e-05	0.000557	CcSEcCtD
Gliclazide—Urinary tract infection—Topiramate—obesity	6.72e-05	0.000557	CcSEcCtD
Gliclazide—Conjunctivitis—Topiramate—obesity	6.72e-05	0.000557	CcSEcCtD
Gliclazide—Gastrointestinal pain—Orlistat—obesity	6.71e-05	0.000556	CcSEcCtD
Gliclazide—Hyperhidrosis—Bupropion—obesity	6.69e-05	0.000554	CcSEcCtD
Gliclazide—Feeling abnormal—Sibutramine—obesity	6.54e-05	0.000542	CcSEcCtD
Gliclazide—Epistaxis—Topiramate—obesity	6.52e-05	0.00054	CcSEcCtD
Gliclazide—Urticaria—Orlistat—obesity	6.52e-05	0.00054	CcSEcCtD
Gliclazide—Gastrointestinal pain—Sibutramine—obesity	6.49e-05	0.000538	CcSEcCtD
Gliclazide—Sinusitis—Topiramate—obesity	6.49e-05	0.000537	CcSEcCtD
Gliclazide—Abdominal pain—Orlistat—obesity	6.48e-05	0.000537	CcSEcCtD
Gliclazide—Body temperature increased—Orlistat—obesity	6.48e-05	0.000537	CcSEcCtD
Gliclazide—Hypotension—Bupropion—obesity	6.47e-05	0.000536	CcSEcCtD
Gliclazide—Agranulocytosis—Topiramate—obesity	6.45e-05	0.000535	CcSEcCtD
Gliclazide—Bradycardia—Topiramate—obesity	6.32e-05	0.000523	CcSEcCtD
Gliclazide—Urticaria—Sibutramine—obesity	6.31e-05	0.000523	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Bupropion—obesity	6.31e-05	0.000522	CcSEcCtD
Gliclazide—Abdominal pain—Sibutramine—obesity	6.28e-05	0.00052	CcSEcCtD
Gliclazide—Body temperature increased—Sibutramine—obesity	6.28e-05	0.00052	CcSEcCtD
Gliclazide—Insomnia—Bupropion—obesity	6.26e-05	0.000519	CcSEcCtD
Gliclazide—Rhinitis—Topiramate—obesity	6.22e-05	0.000515	CcSEcCtD
Gliclazide—Paraesthesia—Bupropion—obesity	6.21e-05	0.000515	CcSEcCtD
Gliclazide—Hepatitis—Topiramate—obesity	6.21e-05	0.000514	CcSEcCtD
Gliclazide—Hypoaesthesia—Topiramate—obesity	6.18e-05	0.000512	CcSEcCtD
Gliclazide—Dyspnoea—Bupropion—obesity	6.17e-05	0.000511	CcSEcCtD
Gliclazide—Pharyngitis—Topiramate—obesity	6.16e-05	0.00051	CcSEcCtD
Gliclazide—Somnolence—Bupropion—obesity	6.15e-05	0.00051	CcSEcCtD
Gliclazide—Oedema peripheral—Topiramate—obesity	6.11e-05	0.000507	CcSEcCtD
Gliclazide—Dyspepsia—Bupropion—obesity	6.09e-05	0.000505	CcSEcCtD
Gliclazide—Hypersensitivity—Orlistat—obesity	6.04e-05	0.000501	CcSEcCtD
Gliclazide—Visual impairment—Topiramate—obesity	5.98e-05	0.000496	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Bupropion—obesity	5.98e-05	0.000495	CcSEcCtD
Gliclazide—Fatigue—Bupropion—obesity	5.97e-05	0.000494	CcSEcCtD
Gliclazide—Pain—Bupropion—obesity	5.92e-05	0.00049	CcSEcCtD
Gliclazide—Constipation—Bupropion—obesity	5.92e-05	0.00049	CcSEcCtD
Gliclazide—Asthenia—Orlistat—obesity	5.89e-05	0.000488	CcSEcCtD
Gliclazide—Erythema multiforme—Topiramate—obesity	5.87e-05	0.000486	CcSEcCtD
Gliclazide—Hypersensitivity—Sibutramine—obesity	5.85e-05	0.000485	CcSEcCtD
Gliclazide—Pruritus—Orlistat—obesity	5.8e-05	0.000481	CcSEcCtD
Gliclazide—Eye disorder—Topiramate—obesity	5.8e-05	0.000481	CcSEcCtD
Gliclazide—Tinnitus—Topiramate—obesity	5.79e-05	0.000479	CcSEcCtD
Gliclazide—Flushing—Topiramate—obesity	5.76e-05	0.000477	CcSEcCtD
Gliclazide—Feeling abnormal—Bupropion—obesity	5.7e-05	0.000473	CcSEcCtD
Gliclazide—Asthenia—Sibutramine—obesity	5.7e-05	0.000472	CcSEcCtD
Gliclazide—Gastrointestinal pain—Bupropion—obesity	5.66e-05	0.000469	CcSEcCtD
Gliclazide—Pruritus—Sibutramine—obesity	5.62e-05	0.000465	CcSEcCtD
Gliclazide—Diarrhoea—Orlistat—obesity	5.61e-05	0.000465	CcSEcCtD
Gliclazide—Chills—Topiramate—obesity	5.57e-05	0.000461	CcSEcCtD
Gliclazide—Urticaria—Bupropion—obesity	5.5e-05	0.000456	CcSEcCtD
Gliclazide—Abdominal pain—Bupropion—obesity	5.47e-05	0.000453	CcSEcCtD
Gliclazide—Body temperature increased—Bupropion—obesity	5.47e-05	0.000453	CcSEcCtD
Gliclazide—Mental disorder—Topiramate—obesity	5.44e-05	0.00045	CcSEcCtD
Gliclazide—Diarrhoea—Sibutramine—obesity	5.43e-05	0.00045	CcSEcCtD
Gliclazide—Dizziness—Orlistat—obesity	5.42e-05	0.000449	CcSEcCtD
Gliclazide—Erythema—Topiramate—obesity	5.4e-05	0.000448	CcSEcCtD
Gliclazide—Malnutrition—Topiramate—obesity	5.4e-05	0.000448	CcSEcCtD
Gliclazide—Flatulence—Topiramate—obesity	5.32e-05	0.000441	CcSEcCtD
Gliclazide—Tension—Topiramate—obesity	5.3e-05	0.000439	CcSEcCtD
Gliclazide—Dizziness—Sibutramine—obesity	5.25e-05	0.000435	CcSEcCtD
Gliclazide—Nervousness—Topiramate—obesity	5.25e-05	0.000435	CcSEcCtD
Gliclazide—Back pain—Topiramate—obesity	5.23e-05	0.000433	CcSEcCtD
Gliclazide—Vomiting—Orlistat—obesity	5.22e-05	0.000432	CcSEcCtD
Gliclazide—Rash—Orlistat—obesity	5.17e-05	0.000429	CcSEcCtD
Gliclazide—Dermatitis—Orlistat—obesity	5.17e-05	0.000428	CcSEcCtD
Gliclazide—Headache—Orlistat—obesity	5.14e-05	0.000426	CcSEcCtD
Gliclazide—Hypersensitivity—Bupropion—obesity	5.1e-05	0.000422	CcSEcCtD
Gliclazide—Tremor—Topiramate—obesity	5.06e-05	0.000419	CcSEcCtD
Gliclazide—Vomiting—Sibutramine—obesity	5.05e-05	0.000418	CcSEcCtD
Gliclazide—Ill-defined disorder—Topiramate—obesity	5.01e-05	0.000415	CcSEcCtD
Gliclazide—Rash—Sibutramine—obesity	5.01e-05	0.000415	CcSEcCtD
Gliclazide—Dermatitis—Sibutramine—obesity	5e-05	0.000414	CcSEcCtD
Gliclazide—Anaemia—Topiramate—obesity	4.99e-05	0.000414	CcSEcCtD
Gliclazide—Headache—Sibutramine—obesity	4.97e-05	0.000412	CcSEcCtD
Gliclazide—Asthenia—Bupropion—obesity	4.97e-05	0.000411	CcSEcCtD
Gliclazide—Agitation—Topiramate—obesity	4.97e-05	0.000411	CcSEcCtD
Gliclazide—Pruritus—Bupropion—obesity	4.9e-05	0.000406	CcSEcCtD
Gliclazide—Nausea—Orlistat—obesity	4.87e-05	0.000404	CcSEcCtD
Gliclazide—Malaise—Topiramate—obesity	4.87e-05	0.000404	CcSEcCtD
Gliclazide—Leukopenia—Topiramate—obesity	4.84e-05	0.000401	CcSEcCtD
Gliclazide—Palpitations—Topiramate—obesity	4.77e-05	0.000396	CcSEcCtD
Gliclazide—Loss of consciousness—Topiramate—obesity	4.75e-05	0.000393	CcSEcCtD
Gliclazide—Diarrhoea—Bupropion—obesity	4.74e-05	0.000392	CcSEcCtD
Gliclazide—Nausea—Sibutramine—obesity	4.72e-05	0.000391	CcSEcCtD
Gliclazide—Cough—Topiramate—obesity	4.71e-05	0.000391	CcSEcCtD
Gliclazide—Convulsion—Topiramate—obesity	4.68e-05	0.000388	CcSEcCtD
Gliclazide—Hypertension—Topiramate—obesity	4.66e-05	0.000386	CcSEcCtD
Gliclazide—Chest pain—Topiramate—obesity	4.6e-05	0.000381	CcSEcCtD
Gliclazide—Arthralgia—Topiramate—obesity	4.6e-05	0.000381	CcSEcCtD
Gliclazide—Myalgia—Topiramate—obesity	4.6e-05	0.000381	CcSEcCtD
Gliclazide—Anxiety—Topiramate—obesity	4.58e-05	0.00038	CcSEcCtD
Gliclazide—Dizziness—Bupropion—obesity	4.58e-05	0.000379	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Topiramate—obesity	4.57e-05	0.000378	CcSEcCtD
Gliclazide—Discomfort—Topiramate—obesity	4.54e-05	0.000377	CcSEcCtD
Gliclazide—Dry mouth—Topiramate—obesity	4.5e-05	0.000373	CcSEcCtD
Gliclazide—Confusional state—Topiramate—obesity	4.45e-05	0.000368	CcSEcCtD
Gliclazide—Vomiting—Bupropion—obesity	4.4e-05	0.000365	CcSEcCtD
Gliclazide—Infection—Topiramate—obesity	4.38e-05	0.000363	CcSEcCtD
Gliclazide—Rash—Bupropion—obesity	4.36e-05	0.000362	CcSEcCtD
Gliclazide—Dermatitis—Bupropion—obesity	4.36e-05	0.000361	CcSEcCtD
Gliclazide—Headache—Bupropion—obesity	4.34e-05	0.000359	CcSEcCtD
Gliclazide—Nervous system disorder—Topiramate—obesity	4.32e-05	0.000358	CcSEcCtD
Gliclazide—Thrombocytopenia—Topiramate—obesity	4.32e-05	0.000358	CcSEcCtD
Gliclazide—Tachycardia—Topiramate—obesity	4.3e-05	0.000357	CcSEcCtD
Gliclazide—Skin disorder—Topiramate—obesity	4.28e-05	0.000355	CcSEcCtD
Gliclazide—Hyperhidrosis—Topiramate—obesity	4.26e-05	0.000353	CcSEcCtD
Gliclazide—Hypotension—Topiramate—obesity	4.12e-05	0.000341	CcSEcCtD
Gliclazide—Nausea—Bupropion—obesity	4.11e-05	0.000341	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Topiramate—obesity	4.02e-05	0.000333	CcSEcCtD
Gliclazide—Insomnia—Topiramate—obesity	3.99e-05	0.00033	CcSEcCtD
Gliclazide—Paraesthesia—Topiramate—obesity	3.96e-05	0.000328	CcSEcCtD
Gliclazide—Dyspnoea—Topiramate—obesity	3.93e-05	0.000326	CcSEcCtD
Gliclazide—Somnolence—Topiramate—obesity	3.92e-05	0.000325	CcSEcCtD
Gliclazide—Dyspepsia—Topiramate—obesity	3.88e-05	0.000322	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Topiramate—obesity	3.81e-05	0.000315	CcSEcCtD
Gliclazide—Fatigue—Topiramate—obesity	3.8e-05	0.000315	CcSEcCtD
Gliclazide—Pain—Topiramate—obesity	3.77e-05	0.000312	CcSEcCtD
Gliclazide—Constipation—Topiramate—obesity	3.77e-05	0.000312	CcSEcCtD
Gliclazide—Feeling abnormal—Topiramate—obesity	3.63e-05	0.000301	CcSEcCtD
Gliclazide—Gastrointestinal pain—Topiramate—obesity	3.61e-05	0.000299	CcSEcCtD
Gliclazide—Urticaria—Topiramate—obesity	3.5e-05	0.00029	CcSEcCtD
Gliclazide—Body temperature increased—Topiramate—obesity	3.49e-05	0.000289	CcSEcCtD
Gliclazide—Abdominal pain—Topiramate—obesity	3.49e-05	0.000289	CcSEcCtD
Gliclazide—Hypersensitivity—Topiramate—obesity	3.25e-05	0.000269	CcSEcCtD
Gliclazide—Asthenia—Topiramate—obesity	3.16e-05	0.000262	CcSEcCtD
Gliclazide—Pruritus—Topiramate—obesity	3.12e-05	0.000258	CcSEcCtD
Gliclazide—Diarrhoea—Topiramate—obesity	3.02e-05	0.00025	CcSEcCtD
Gliclazide—Dizziness—Topiramate—obesity	2.92e-05	0.000242	CcSEcCtD
Gliclazide—Vomiting—Topiramate—obesity	2.8e-05	0.000232	CcSEcCtD
Gliclazide—Rash—Topiramate—obesity	2.78e-05	0.00023	CcSEcCtD
Gliclazide—Dermatitis—Topiramate—obesity	2.78e-05	0.00023	CcSEcCtD
Gliclazide—Headache—Topiramate—obesity	2.76e-05	0.000229	CcSEcCtD
Gliclazide—Nausea—Topiramate—obesity	2.62e-05	0.000217	CcSEcCtD
Gliclazide—CYP2C19—Metabolism—APOA5—obesity	5.11e-06	7.07e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IRS1—obesity	5.1e-06	7.06e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—G6PD—obesity	5.1e-06	7.05e-05	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—APOA1—obesity	5.1e-06	7.05e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—HK1—obesity	5.04e-06	6.96e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SREBF2—obesity	5.04e-06	6.96e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CD36—obesity	5.03e-06	6.96e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CB—obesity	5.02e-06	6.94e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PRKAR2B—obesity	5.01e-06	6.93e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—DCN—obesity	4.98e-06	6.89e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTGS2—obesity	4.98e-06	6.88e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—AGT—obesity	4.97e-06	6.87e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IGF1—obesity	4.92e-06	6.8e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—AKT2—obesity	4.92e-06	6.8e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—POMC—obesity	4.91e-06	6.8e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CG—obesity	4.89e-06	6.77e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—INS—obesity	4.89e-06	6.76e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CLOCK—obesity	4.88e-06	6.75e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SLC22A1—obesity	4.88e-06	6.75e-05	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PIK3CA—obesity	4.87e-06	6.73e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—obesity	4.87e-06	6.73e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—LPA—obesity	4.86e-06	6.73e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CPT1A—obesity	4.84e-06	6.7e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—obesity	4.82e-06	6.67e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—APOA1—obesity	4.81e-06	6.65e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCL2—obesity	4.81e-06	6.65e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—LPIN1—obesity	4.76e-06	6.58e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SULT2A1—obesity	4.75e-06	6.57e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GLP1R—obesity	4.75e-06	6.57e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NAMPT—obesity	4.75e-06	6.57e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IGF1—obesity	4.73e-06	6.54e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CD—obesity	4.72e-06	6.53e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AKT2—obesity	4.72e-06	6.53e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PPARG—obesity	4.72e-06	6.53e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—LIPC—obesity	4.72e-06	6.53e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GCK—obesity	4.72e-06	6.53e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—APOC3—obesity	4.69e-06	6.49e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—DPYD—obesity	4.68e-06	6.47e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—obesity	4.68e-06	6.47e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—SERPINE1—obesity	4.67e-06	6.46e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—APOA5—obesity	4.66e-06	6.45e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—POMC—obesity	4.66e-06	6.44e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CETP—obesity	4.55e-06	6.3e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CD—obesity	4.54e-06	6.28e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—AGT—obesity	4.53e-06	6.26e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—RHOA—obesity	4.51e-06	6.23e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SDC1—obesity	4.5e-06	6.23e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PRKAR2B—obesity	4.5e-06	6.23e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SERPINE1—obesity	4.49e-06	6.21e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—DCN—obesity	4.47e-06	6.18e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3R1—obesity	4.46e-06	6.17e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NOS3—obesity	4.46e-06	6.17e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SLC22A1—obesity	4.45e-06	6.15e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CLOCK—obesity	4.45e-06	6.15e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—obesity	4.44e-06	6.14e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AKR1C3—obesity	4.43e-06	6.13e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—obesity	4.4e-06	6.08e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—obesity	4.39e-06	6.07e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—obesity	4.39e-06	6.07e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TYK2—obesity	4.37e-06	6.04e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SCARB1—obesity	4.36e-06	6.03e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CPT1A—obesity	4.35e-06	6.01e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GLP1R—obesity	4.33e-06	5.99e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SULT2A1—obesity	4.33e-06	5.99e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—RHOA—obesity	4.33e-06	5.99e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CD—obesity	4.3e-06	5.95e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NOS3—obesity	4.29e-06	5.93e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3R1—obesity	4.29e-06	5.93e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—DPYD—obesity	4.26e-06	5.9e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NAMPT—obesity	4.26e-06	5.9e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—obesity	4.24e-06	5.86e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GCK—obesity	4.24e-06	5.86e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—LIPC—obesity	4.24e-06	5.86e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SREBF1—obesity	4.23e-06	5.85e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—APOC3—obesity	4.21e-06	5.82e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—obesity	4.18e-06	5.78e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GOT2—obesity	4.12e-06	5.69e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CB—obesity	4.12e-06	5.69e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PRKAR2B—obesity	4.1e-06	5.68e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CETP—obesity	4.09e-06	5.65e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—DCN—obesity	4.08e-06	5.64e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3R1—obesity	4.06e-06	5.62e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SDC1—obesity	4.04e-06	5.59e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—FASN—obesity	4.03e-06	5.57e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—BCHE—obesity	4.01e-06	5.55e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—obesity	4e-06	5.54e-05	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—AKT1—obesity	3.98e-06	5.5e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AKR1C3—obesity	3.98e-06	5.5e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CPT1A—obesity	3.96e-06	5.48e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MTOR—obesity	3.96e-06	5.47e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CB—obesity	3.96e-06	5.47e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SCARB1—obesity	3.91e-06	5.41e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NAMPT—obesity	3.89e-06	5.38e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP2E1—obesity	3.87e-06	5.35e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—obesity	3.87e-06	5.34e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GCK—obesity	3.86e-06	5.34e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—LIPC—obesity	3.86e-06	5.34e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—obesity	3.86e-06	5.34e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—APOC3—obesity	3.84e-06	5.31e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NQO1—obesity	3.83e-06	5.29e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—obesity	3.81e-06	5.27e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—obesity	3.81e-06	5.27e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SREBF1—obesity	3.8e-06	5.26e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CB—obesity	3.75e-06	5.18e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CETP—obesity	3.73e-06	5.15e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTGS2—obesity	3.71e-06	5.14e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GOT2—obesity	3.7e-06	5.11e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SDC1—obesity	3.69e-06	5.1e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GCG—obesity	3.67e-06	5.08e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SLC2A4—obesity	3.67e-06	5.08e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3R1—obesity	3.65e-06	5.04e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AKR1C3—obesity	3.63e-06	5.01e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYCS—obesity	3.62e-06	5.01e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—FASN—obesity	3.62e-06	5e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—BCHE—obesity	3.6e-06	4.98e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SCARB1—obesity	3.57e-06	4.94e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GGT1—obesity	3.55e-06	4.92e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GOT1—obesity	3.55e-06	4.92e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—obesity	3.52e-06	4.87e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NCOA1—obesity	3.5e-06	4.84e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP2E1—obesity	3.48e-06	4.81e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—obesity	3.48e-06	4.81e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SREBF1—obesity	3.47e-06	4.79e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—STK11—obesity	3.45e-06	4.77e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP19A1—obesity	3.45e-06	4.77e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MMP9—obesity	3.44e-06	4.75e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NQO1—obesity	3.44e-06	4.75e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GOT2—obesity	3.37e-06	4.66e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—obesity	3.37e-06	4.65e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MAPK8—obesity	3.34e-06	4.62e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—obesity	3.33e-06	4.61e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—obesity	3.32e-06	4.6e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—FASN—obesity	3.3e-06	4.56e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SLC2A4—obesity	3.3e-06	4.56e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GCG—obesity	3.3e-06	4.56e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—BCHE—obesity	3.29e-06	4.54e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYCS—obesity	3.25e-06	4.5e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—COMT—obesity	3.21e-06	4.44e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GGT1—obesity	3.19e-06	4.41e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GOT1—obesity	3.19e-06	4.41e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP2E1—obesity	3.17e-06	4.38e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GNB3—obesity	3.16e-06	4.37e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PPARGC1A—obesity	3.16e-06	4.37e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CA—obesity	3.16e-06	4.37e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—HMOX1—obesity	3.15e-06	4.35e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NCOA1—obesity	3.14e-06	4.35e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NQO1—obesity	3.13e-06	4.33e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—STK11—obesity	3.1e-06	4.28e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP19A1—obesity	3.1e-06	4.28e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GNAS—obesity	3.08e-06	4.26e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—obesity	3.07e-06	4.24e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CA—obesity	3.06e-06	4.23e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—STAT3—obesity	3.06e-06	4.23e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—obesity	3.04e-06	4.2e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—APOB—obesity	3.02e-06	4.17e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GCG—obesity	3e-06	4.15e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SLC2A4—obesity	3e-06	4.15e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYCS—obesity	2.97e-06	4.1e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TGFB1—obesity	2.95e-06	4.08e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GOT1—obesity	2.91e-06	4.02e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GGT1—obesity	2.91e-06	4.02e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—LPL—obesity	2.88e-06	3.98e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—COMT—obesity	2.88e-06	3.98e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NCOA1—obesity	2.87e-06	3.96e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MYC—obesity	2.84e-06	3.93e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GNB3—obesity	2.84e-06	3.93e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PPARGC1A—obesity	2.84e-06	3.93e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TGFB1—obesity	2.83e-06	3.92e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—HMOX1—obesity	2.83e-06	3.91e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—STK11—obesity	2.82e-06	3.91e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP19A1—obesity	2.82e-06	3.91e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GPX1—obesity	2.81e-06	3.89e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GNAS—obesity	2.77e-06	3.82e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CD36—obesity	2.74e-06	3.78e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—APOB—obesity	2.71e-06	3.74e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—COMT—obesity	2.63e-06	3.63e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—MTHFR—obesity	2.59e-06	3.59e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PPARGC1A—obesity	2.59e-06	3.58e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GNB3—obesity	2.59e-06	3.58e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—LPL—obesity	2.59e-06	3.58e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—AKT1—obesity	2.58e-06	3.57e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—HMOX1—obesity	2.58e-06	3.56e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PPARA—obesity	2.54e-06	3.52e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GPX1—obesity	2.52e-06	3.49e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GNAS—obesity	2.52e-06	3.49e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CA—obesity	2.51e-06	3.47e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—AKT1—obesity	2.5e-06	3.46e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—APOB—obesity	2.47e-06	3.41e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AGT—obesity	2.46e-06	3.41e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CD36—obesity	2.46e-06	3.4e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—APOE—obesity	2.41e-06	3.34e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CA—obesity	2.41e-06	3.33e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CAV1—obesity	2.39e-06	3.31e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—APOA1—obesity	2.39e-06	3.3e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—LPL—obesity	2.36e-06	3.26e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—MTHFR—obesity	2.33e-06	3.22e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GPX1—obesity	2.3e-06	3.18e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—obesity	2.29e-06	3.16e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PPARA—obesity	2.28e-06	3.16e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CD36—obesity	2.24e-06	3.1e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AGT—obesity	2.21e-06	3.06e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CG—obesity	2.18e-06	3.01e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—APOE—obesity	2.17e-06	3e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CAV1—obesity	2.15e-06	2.97e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—APOA1—obesity	2.14e-06	2.96e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL6—obesity	2.14e-06	2.95e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—MTHFR—obesity	2.12e-06	2.94e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PPARG—obesity	2.1e-06	2.91e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PPARA—obesity	2.08e-06	2.88e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—POMC—obesity	2.07e-06	2.87e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—INS—obesity	2.06e-06	2.85e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—obesity	2.05e-06	2.84e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—AKT1—obesity	2.05e-06	2.84e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AGT—obesity	2.02e-06	2.79e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—APOE—obesity	1.98e-06	2.73e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AKT1—obesity	1.97e-06	2.72e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CAV1—obesity	1.96e-06	2.71e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CG—obesity	1.96e-06	2.7e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—APOA1—obesity	1.95e-06	2.7e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CD—obesity	1.92e-06	2.65e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PPARG—obesity	1.89e-06	2.61e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—obesity	1.87e-06	2.59e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—POMC—obesity	1.86e-06	2.57e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—INS—obesity	1.85e-06	2.56e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NOS3—obesity	1.81e-06	2.5e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3R1—obesity	1.81e-06	2.5e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CG—obesity	1.78e-06	2.47e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PPARG—obesity	1.72e-06	2.38e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CD—obesity	1.72e-06	2.38e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—POMC—obesity	1.7e-06	2.35e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALB—obesity	1.7e-06	2.35e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—INS—obesity	1.69e-06	2.33e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CB—obesity	1.67e-06	2.31e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTGS2—obesity	1.65e-06	2.29e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3R1—obesity	1.62e-06	2.25e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NOS3—obesity	1.62e-06	2.25e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CD—obesity	1.57e-06	2.17e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALB—obesity	1.55e-06	2.14e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CB—obesity	1.5e-06	2.07e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTGS2—obesity	1.49e-06	2.05e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NOS3—obesity	1.48e-06	2.05e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3R1—obesity	1.48e-06	2.05e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CB—obesity	1.37e-06	1.89e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTGS2—obesity	1.35e-06	1.87e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CA—obesity	1.02e-06	1.41e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CA—obesity	9.14e-07	1.26e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CA—obesity	8.33e-07	1.15e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AKT1—obesity	8.31e-07	1.15e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AKT1—obesity	7.46e-07	1.03e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AKT1—obesity	6.81e-07	9.41e-06	CbGpPWpGaD
